1-methylpiperidine

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

other information

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Study meets generally accepted scientific standards with restrictions due to the limited documentation.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1970

Report date:

1970

Materials and methods

Principles of method if other than guideline:

BASF test
Aqueous preparations of the test substance were injected into the peritoneal cavity of the mice. Group-wise documentation of clinical signs was performed over the 7-day study period. Body weight was determined before the start of the study only, as it was needed for determination of dose. The clinical signs and findings were reported in summary form.

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

1-methylpiperidine

EC Number:

210-959-9

EC Name:

1-methylpiperidine

Cas Number:

626-67-5

Molecular formula:

C6H13N

IUPAC Name:

1-methylpiperidine

Details on test material:

- Name of test material (as cited in study report): Methylpiperidine
- Physical state: liquid
- Analytical purity: no data

Test animals

Species:

mouse

Strain:

not specified

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Mean body weight at study initiation: 33.7 ± 2.86 g (males), 29.4 ± 2.99 g (females)

ENVIRONMENTAL CONDITIONS
no details given

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

water

Details on exposure:

VEHICLE
- Concentration in vehicle: The doses were applied as 0.5 % (50 µL/kg bw), 1 % (100 µL/kg bw), 2 % (125, 160 and 200 µL/kg) , or 20 % (1600 µL/kg bw) v/v preparations of the test substance in aqua dest.
- Justification for choice of vehicle: soluble in water

MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg

Doses:

50, 100, 125, 160, 200, and 1600 µL/kg bw (corresponding to approx. 41, 82, 102, 131, 163 and 1306 mg/kg bw; calculation based on density of 0.8165 g/cm³)

No. of animals per sex per dose:

5

Control animals:

no

Details on study design:

- Duration of observation period following administration: 13 days
- Frequency of observations and weighing: Cageside observations were performed several times on the day of administration and daily on workdays during observation period. Body weights were determined at test start for dose determination.
- Necropsy of survivors performed: no
- Other examinations performed: clinical signs, gross-pathological investigation

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

94 mg/kg bw

Based on:

test mat.

Remarks on result:

other: corresponding to 115 µL/kg bw; calculation was based on a density of 0.8165 g/cm³

Mortality:

1306 mg/kg bw: 5/5 males and females died within 15 min after administration;
163 mg/kg bw: males: 4/5 animals died within 24 hours; females: 1/5 animals died within 1 hour, 4/5 within 7 days and 5/5 within 14 days after administration;
131 mg/kg bw: males: 2/5 males died within 24 hours, 4/5 within 48 hours and 5/5 within 7 days; females: 3/5 animals died within 24 hours; 5/5 within 7 days;
102 mg/kg bw: males: 3/5 animals died within 48 hours; females: 4/5 animals died within 7 days and 5/5 within 14 days.
82 and 41 mg/kg bw: 0/5 males and 0/5 females died, respectively

Clinical signs:

1306 mg/kg bw: immediately after application of the test substance sedate behaviour, accelerated respiration, sunken flanks.
41 to 163 mg/kg bw: immediately after injection, high stepping gait, sunken flanks, sedate behaviour, accelerated respiration, spasmodic convulsions. Ca. 4 hours after treatment sedate behaviour, partly abdominal position, irregular accelerated respiration, closed eyes, scrubby fur, crouched position. From day 7 no abnormalities were detectable in surviving animals.

172 to 34 mg/kg bw: after treatment intermittent respiration, abdominal position and apathy. On day 2 moderate food intake and scrubby fur. On day 2 adhering eye lids and poor general state until death.
27 to 21 mg/kg bw: after treatment slightly accelerated respiration, moderate food intake. On day one no abnormalities detectable.

Body weight:

No data

Gross pathology:

Deceased animals: putrefaction in all animals, three times adhesions between liver and stomach, 5 times intraabdominal adhesion compared to putrefaction.
Sacrifized animals: three times adhesions at the liver region, twice conjunctive tissue adhesions between intestinal loops, substance incorporation between liver and stomach. Otherwise, no abnormalities detected in organs.